๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc)

โœ Scribed by C. Boni; G. Bisagni; L. Savoldi; G. Moretti; E. Rondini; M. Sassi; A. Zadro; T. De Pas; V. Franciosi; A. Pazzola; R. Vignoli; M.C. Banzi; V. Pajetta

Publisher
John Wiley and Sons
Year
2000
Tongue
French
Weight
55 KB
Volume
87
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Teniposide (VM-26) as a single drug trea
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II study of the Southwest Oncology Group
โœ Petre N. Grozea; John J. Crowley; Vikki A. Canfield; Laura Kingsbury; S. William ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 1 views

## Background: Teniposide (vm-26) was reported to have activity in small cell lung carcinoma (sclc). the authors performed a phase ii study of teniposide as a treatment for patients with previously untreated extensive sclc. ## Methods: The study was open to patients with a histologic or cytologic

The combination of cisplatin, doxorubici
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research
โœ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 482 KB ๐Ÿ‘ 1 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat